Strengths

Strong liquidity with a current ratio of 4.50 and quick ratio of 4.46.

Balance sheet remains conservative with debt-to-equity of 0.13 and debt-to-assets of 0.10.

Gross margin is still healthy at 41.8%, supporting the core commercial model.

Weaknesses

Profitability remains deeply negative, with net margin at -109.9% and operating margin at -113.7%.

Cash generation is still negative, with operating cash flow per share at -3.09 and free cash flow per share at -3.13.

Valuation remains extremely rich at 189.4x sales despite ongoing losses.

Opportunities

A strong cash position of $2.09 per share provides runway to fund development and commercialization.

High R&D intensity at 94.2% of revenue suggests continued pipeline investment that could support future product growth.

Low leverage leaves room for strategic financing or partnership activity if needed.

Threats

Sustained losses and negative operating cash flow increase financing risk if execution does not improve.

Very high operating expense intensity, including SG&A at 19.9x revenue, keeps pressure on margins.

The stock remains vulnerable to multiple compression given the combination of negative earnings and a premium sales multiple.

Overall Score